anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will be accrued in alternating dose levels. The two distinct areas of dose escalations (pelvic lymph node and prostate lesion) will take place one at a time. Minimum waiting periods will be assigned between each dose cohort to observe toxicity. The phase I portion of the study will be completed when dose limiting toxicity is reached or when a sufficiently high dose level (i.e.,5.5 Gy per fraction to a total 27.5 Gy for pelvic lymph node region and 11Gy per fraction to a total of 55Gy to the prostate lesion), is attained to consider the therapy likely to be efficacious. All patients will be treated with a total of 24 months of androgen suppression therapy (ADT). Radiation therapy will start 8-12 weeks after initiation of ADT.

No. Patients for each cohort: 7-15 Cohort 1: 9.5 Gy per fraction to prostate/SV, 10 Gy per fraction to prostate lesion, 4.5Gy per fraction to pelvic lymph node region for 5 fractions for a total of 47.5 / 50 / 22.5 Gy to Prostate+SV /Prostate lesions/Nodes Cohort 2: 9.5 Gy per fraction to prostate/SV, 10 Gy per fraction to prostate lesion, 5Gy per fraction to pelvic lymph node region for 5 fractions for a total of 47.5 / 50 / 25 Gy to Prostate+SV /Prostate lesions/Nodes Cohort 3: 9.5 Gy per fraction to prostate/SV, 10.5 Gy per fraction to prostate lesion, 5Gy per fraction to pelvic lymph node region for 5 fractions for a total of 47.5 / 52.5 / 25 Gy to Prostate+SV /Prostate lesions/Nodes Cohort 4: 9.5 Gy per fraction to prostate/SV, 10.5 Gy per fraction to prostate lesion, 5.5 Gy per fraction to pelvic lymph node region for 5 fractions for a total of 47.5 / 52.5 / 27.5 Gy to Prostate+SV /Prostate lesions/Nodes Cohort 5: 9.5 Gy per fraction to prostate/SV, 11 Gy per fraction to prostate lesion, 5.5 Gy per fraction to pelvic lymph node region for 5 fractions for a total of 47.5 / 55 / 27.5 Gy to Prostate+SV /Prostate lesions/Nodes
Start isoproterenol hydrochloride injection at the lowest recommended dose and increase the rate of administration gradually if necessary while carefully monitoring the patient. The usual route of administration is by intravenous infusion or bolus intravenous injection. In dire emergencies, the drug may be administered by intracardiac injection. If time is not of the utmost importance, initial therapy by intramuscular or subcutaneous injection is preferred.

There are no well-controlled studies in children to establish appropriate dosing; however, the American Heart Association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1 mcg/kg/min.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Such solution should not be used.

Discard unused portion.
The present invention relates to the technical field of food processing and discloses tableting sugar, a preparation method and an application thereof. The disclosed tableting sugar is good in mouthfeel and high in vitamin C content and has a relative strong free radical scavenging function. The disclosed tableting sugar consists of the following raw materials: procyanidins, lactose, sorbitol, xylitol, maltitol, mannitol, beta-cyclodextrin, aspartame, citric acids, micropowder silica gels, magnesium stearate, a wetting agent and mint essential oil. The present invention also discloses the preparation method of the tableting sugar. The method comprises the following steps: step 1, raw material crushing and crushed raw material screening; step 2, OPC clathrate preparing; step 3, soft material preparing and granulating; and step 4, drying, granule separating, total mixing, tableting, sterilizing, packaging, and product obtaining. The present invention also discloses the application of the tableting sugar in the productions of food, health products and medicines.
FIELD: medicine, pharmacology. SUBSTANCE: invention involves antiviral composition comprising the preliminary activated component of atomic silver, atomic silver stabilizing agent taken among order of synthetic or natural polymers of medicinal designation and also dimexide, hydrogen peroxide and distilled water. Invention relates to method of preparing active component comprising of atomic silver, stabilizing agent and distilled water. Method of treatment of infected patients involves rectal administration of curative composition in lower rectum as microenema in volume 100 ml, once per 24 h, for 10 days with course repetition in 7-10 days up to negative result of blood analysis for HIV-infection. The advantage of invention involves development of method of effect on human HIV cells resulting to inactivation of virus. Invention can be used for treatment of patients infected with HIV-infection and other viruses and relates to antiviral composition, method of activation of its active component and treatment of HIV-infected patients using this composition. EFFECT: improved method of preparing and treatment, valuable medicinal properties. 4 cl, 3 ex
The utility model discloses a bagged Chinese medicinal tablet capable of decocting and separately packing, which comprises granular Chinese herbs, an external pack bag for containing the granular Chinese herbs therein and an interior pack bag enveloped in the external pack bag. Concavo-convex literal makers are engraved in the peripheral of the external pack bag or the interior pack bag. A tear-off line having one end connected to a label card is arranged on the interior pack bag. A tear-off opening is arranged at the external pack bag. The external pack bag is dustproof and damp-proof and anti-mixing. The interior pack bag is water resistant for being decocted or leaked through. The concavo-convex literal makers and the label card are marked with herb information such like name, weight, manufacturer, date, etc. to effectively ensure herb accuracy and reliable herb identification to satisfy the implement of Chinese medicinal tablet license number management system. The utility model has prearranged measure specs to satisfy any dosage demands of Chinese herbs. When using, user tears off the external pack bag, takes out the interior pack bag therefrom, and then decocts the granular Chinese herbs.
With expansion of chimeric antigen receptor (CAR) T cell therapy and broader utilization of anti-cytokine directed therapeutics for toxicity mitigation, the routine assessment of cytokines may enhance understanding of toxicity profiles, guide therapeutic interventions, and facilitate cross-trial comparisons. As specific cytokine elevations can correlate with and provide insights into CAR T cell toxicity, mitigation strategies, and response, we explored the reporting of cytokine detection methods and assessed for the correlation of cytokines to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) across clinical trials. In this analysis, we reviewed 21 clinical trials across 60 manuscripts that featured a US Food and Drug Administration-approved CAR T cell construct or one of its predecessors. We highlight substantial variability and limited reporting of cytokine measurement platforms and panels used across CAR T cell clinical trials. Specifically, across 60 publications, 28 (46.7%) did not report any cytokine data, representing 6 of 21 (28.6%) clinical trials. In the 15 trials reporting cytokine data, at least 4 different platforms were used. Furthermore, correlation of cytokines with ICANS, CRS, and CRS severity was limited. Considering the fundamental role of cytokines in CAR T cell toxicity, our manuscript supports the need to establish standardization of cytokine measurements as a key biomarker essential to improving outcomes of CAR T cell therapy.
A drug carrier and a method of fabricating the same are provided. The drug carrier is used to cover boron-containing drugs. The drug carrier includes a negatively charged polysaccharide inner core and a positively charged polysaccharide outer shell. The negatively charged polysaccharide inner core covers the boron-containing drugs. The positively charged polysaccharide outer shell covers a surface of the negatively charged polysaccharide inner core. The drug carrier can be transferred and gathered near a tumor tissue. Also, a leakage of the boron-containing drugs in the transfer process is low, so as to reduce damage of normal cells.
A disinfectant, medicinal, veterinary, shamppoo and dental hygienic composition contains trichloracetic acid together with salicylic acid or an alkali metal salicylate or sulpho salicylic acid, the amount of trichloracetic acid being greater than the amount of the second substance and preferably in the ratio of 12 : 1 to about 12 : 2.  The mixture is preferably used as dilutions or dispersions in liquid, e.g. mainly aqueous, mainly alcoholic, mainly hydroalcoholic or mainly oily, pasty or solid carriers in which the trichloracetic acid content is preferably 3 to 15 per cent.  The composition using a mainly aqueous or mainly oily carrier and having a trichloracetic acid content of about 3 per cent may be employed, preferably with perfume added, on the body to protect skin and mucous membranes against infection.  When the carrier is mainly aqueous the composition is used for tooth hygiene, a disinfectant for buildings &c. and as a sheep dip or pediluvium, and may further contain a water-soluble detergent, preferably of the active anion type, e.g. a mixture of sodium alkyl sulphonates containing from 8 to 18 carbon atoms, preferably in the proportion of about 6 per cent or more by weight with perfume when it may be employed as a shampoo.  The carrier may also be a soap preferably derived from a fatty acid or the conventional components of tooth paste and soaps to provide a tooth hygienic composition.  An example of an aqueous solution for treating bovines orally is crystallized trichloracetic acid 30 g., salicylic acid or sodium salicylate or sulfo salicylic acid 2.5 g., Glycerol 60 g., with water, to make up 1000 g.  An example of an oily solution for treating the animal's body and litter is crystallized trichloracetic acid 30 g., salicylic acid 2.5 g., dimethyl phthalate 5 g., ether 200 g. with vegetable oil to make up 1000 g.
In this feasibility study the researchers propose to conduct a 5-day tDCS treatment protocol in hospitalized adult patients with TRD, with each treatment session lasting for 30 minutes, delivered twice daily, for a total of 10 stimulations over 5 days. Before and after the 5-day tDCS treatment protocol, assessments will include Montgomery-Asberg Depression Rating Scale (MADRS) to measure depressive symptoms, Snaith-Hamilton Pleasure Scale (SHAPS) to measure anhedonia, Stroop Test to measure memory and executive function, Revised Hopkins Verbal Learning Test (HVLT-R) to test verbal learning and memory, and Digital Symbol Coding Test (DSCT) to measure working memory. Electroencephalography (EEG) for objective electrophysiologic data will also be collected before and after tDCS. A wireless EEG unit (CGX, Cognionic, Inc.) will be used to collect EEG and peak alpha frequency (PAF) as potential target engagement marker for tDCS. The PAF measures the highest magnitude within the alpha range of brain oscillations, thought to reflect cognitive performance. Other potential predictors of treatment response measures collected at baseline include Adverse Childhood Experiences (ACE), premorbid intelligence quotient (pIQ), Wide Range Achievement Reading Test (WRART), and Socioeconomic Status (SES).
Twenty healthy subjects will be recruited. Every subject will be randomized in 6 groups and studied on 3 separate days in random order with 1 week intervals. These participants will consume protein enriched bar, commercial cereal bar, or water followed by a standardized diet (gimbap). For study outcomes, food intake, appetite and satiety (visual analog scale), plasma glucose, and satiety related hormone will be measured. Blood sampling will be done before 15 min of breakeast, at the moment of start of breakfast (0 min), and then 30, 60, 90, 120 min. Plasma glucose levels, total/active GLP-1, ghrelin, total PYY will be measured.
Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
An enhancing composition comprising a solvent and a base compound creates an alkaline environment for activating peroxide whiteners and accelerating the formation of free radicals from the peroxide to effect the oxidation of organic molecules causing staining of the dentition. In one embodiment, potassium hydroxide is dissolved in water to form a strongly alkaline liquid. A surfactant may also be included to clean the surfaces of the user's teeth in advance of application of the whitening composition. A peroxide may be added to the enhancing composition to provide a tooth whitening. Other additives for taste, texture, viscosity, and other oral care or oral hygiene purposes may also be included in the enhancing composition. The enhancing composition may be used for advance application to the dentition before a whitening compound. In addition, a rinse may be used after the whitening composition to neutralize the alkaline environment.
Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof are described. The methods involve providing anesthesia to the site where the capsaicin or analogues thereof is to be administrered, and then administering an effective concentration of capsaicin to the joint. The anesthesia can be provided directly to the site, or at remote site that causes anesthesia at the site where the capsaicin is to be administered . For example, epidurel regional anesthesia can be provided to patients to which the capsaicin is to be administered at a site located from the waist down. By pretreating the site with the anesthetic, a significantly higher concentration of capsaicin can be used. Effective concentrations of capsaicin or analogues thereof range from between 0.01 and 10 % by weight, preferably between t and 7.5 % by weight, and more preferably, about 5 % by weight. This provides for greater and more prolonged pain relief, for periods of time ranging from one week to several weeks. In some cases the pain relief may be more sustained because the disease that underlies the pain may improve due to a variety of factors including enhancement of physical therapy due to less pain in the soft tissues which may foster enhanced mobilization of soft tissues, tendons, and joints.
Provided herein are methods and compositions useful for the replenishment of blood cells in a mammal after exposure to therapeutic radiation or drugs. Radiation illness can be reduced in animals by treatment with substance P analogs. In one embodiment, granulocytes can be regenerated after therapeutic radiation by the administration of a substance P analog. In one embodiment, substance P analogs are useful for reducing PARP activity or PARP expression. In one embodiment, substance P analogs are useful for preventing, reducing or ameliorating adverse effects of drugs. In one embodiment, drug induced blood dyscrasias can be ameliorated by the methods and compositions provided herein.
Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
PURPOSE: To report a case of bilateral retinal hemorrhages in a patient undergoing two separate endovascular interventions for bilateral cerebral aneurysms.
METHODS: A comprehensive ophthalmic examination was performed after the patient underwent each of two separate endovascular interventions for bilateral cerebral aneurysms. Multimodal imaging including widefield pseudocolor fundus photography, optical coherence tomography, and widefield fluorescein angiography was obtained. A systemic workup including genetic testing and hypercoagulability studies was performed.
RESULTS: Dilated fundus examination revealed new visually significant ipsilateral retinal hemorrhages after each endovascular procedure. Fluorescein angiography showed evidence of a peripheral retinal microangiopathy present in both eyes before the patient underwent her second endovascular procedure. Systemic workup revealed persistently elevated serum anticardiolipin IgM antibody levels at >99th percentile.
CONCLUSION: Retinal complications after endovascular intracranial interventions are uncommon. This patient who developed bilateral retinal complications was found to have persistently elevated anticardiolipin antibody levels, a risk factor for thrombosis. Patients who develop retinal complications after endovascular intracranial intervention may benefit from systemic workup for hypercoagulable conditions.
In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
A total of 100 patients with carpo-metacarpal (CMC) arthritis will be enrolled in the study. The design of the study is a prospective non-blinded, non-randomized control study. Enrollment will occur at the time of initial clinic visit. All patients presenting with CMC arthritis and deemed appropriate for surgery will be considered for screened for inclusion. As a part of routine workup for CMC arthritis patients receive a hand xray. Specific attendings will perform their preferred technique for CMC arthritis: two perform denervation of the CMC joint, and two perform trapeziectomy with ligament reconstruction tendon-interposition (LRTI) only per their normal clinical practice.

Pre-operative and peri-operative care will be unchanged from standard patient care. Both procedures are outpatient procedures, usually performed under regional anesthesia and patients go home the same day. Patients are discharged with a standard thumb spica splint which is removed on their first clinic appointment which is generally post-operative day 7.

Patients enrolled in the study will have additional follow up at the 3, 6, 12 and 24 month time points. At the 3, 6, 12 and 24 month time points patients will be asked to come to clinic for evaluation with 1) a standard hand questionnaire the Michigan Hand Questionnaire, 2) lateral pinch strength, grip strength and range of motion testing, 3) Kapandji score, 4) visual analog pain scale. Each visit will take approximately 15 minutes. Patients who are unable to follow up in clinic will be given a phone questionnaire with the Michigan Hand Questionnaire, visual analog pain scale and opiate usage. There is no monetary compensation for participation in the study.
Serotonergic antidepressants, including mirtazapine tablets, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7)] . Serotonin syndrome can also occur when these drugs are used alone. 

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

The concomitant use of mirtazapine tablets with MAOIs is contraindicated. In addition, do not initiate mirtazapine tablets in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking mirtazapine tablets, discontinue mirtazapine tablets before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7)] . 

Monitor all patients taking mirtazapine tablets for the emergence of serotonin syndrome. Discontinue treatment with mirtazapine tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of mirtazapine tablets with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
ETHNOPHARMACOLOGICAL RELEVANCE: Optimized New Shengmai Powder (ONSMP) is a traditional Chinese medicine (TCM) formula for heart failure treatment. MAPK signaling pathway is the key driver of myocardial fibrosis in heart failure. However, the mechanism of ONSMP on myocardial fibrosis and MAPK signaling pathway remains unclear.
AIM OF THE STUDY: To evaluate the effect of ONSMP against myocardial fibrosis in heart failure and the underlying mechanisms.
MATERIALS AND METHODS: Firstly, UHPLC-Q-Exactive-MS/MS was used to identify the active components in ONSMP. Secondly, a rat model of heart failure was established by ligating the left anterior descending branch of the coronary artery. After four weeks of intragastric administration of ONSMP, we used various classic tests, including echocardiography, exhaustive swimming, cardiopulmonary coefficient, heart failure markers, and cardiac pathological section, to assess the prescription's anti-myocardial fibrosis in heart failure properties. AGEs, Ang Ⅱ, VEGF, CTGF, and TGFβ levels in rat serum were quantified using ELISA. The positive expression of p-ERK1/2 and p-JNK1/2 of rat myocardium was determined immunohistochemical. The protein and mRNA levels of genes involved in the MAPK signaling pathway and myocardial fibrosis were measured using western blotting or real-time PCR.
RESULTS: The main components of ONSMP that regulate the MAPK signaling pathway are isorhamnetin, kaempferol, quercetin, and tanshinone ⅡA. ONSMP ameliorated cardiac function and exercise tolerance and reduced cardiopulmonary coefficient, heart failure marker levels, and myocardial fibrosis in the heart failure rats. In addition, ONSMP diminished the serum MAPK pathway activator levels, positive expression level of p-ERK1/2 and p-JNK1/2, protein and mRNA levels of components of the MAPK signaling pathway in the myocardial tissue of heart failure rat, indicating that it inhibits MAPK signaling pathway.
CONCLUSIONS: ONSMP delayed heart failure by inhibiting myocardial fibrosis via the MAPK signaling pathway.